A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

The FDA has accepted the sNDA for avatrombopag for the treatment of thrombocytopenia in pediatric patients aged 1 year and ...

The US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug ...

Thrombocytopenia Thrombocytopenia is a condition denoted by a low number of blood platelets. Given that these blood platelets ...

Eltrombopag shows improved platelet counts and quality-of-life outcomes in treating pediatric immune thrombocytopenia.

Heparin-Induced Thrombocytopenia (HIT) is a life-threatening complication following heparin exposure. The webinar presentation will discuss the pathogenesis, incidence, clinical and laboratory ...

Common types of blood disorders include anemia, where there is a deficiency of red blood cells or hemoglobin, leading to fatigue and weakness, and thrombocytopenia, characterized by low platelet ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune thrombocytopenia (ITP) in the adult population, met its primary endpoint.

The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid ...

Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...